Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
8 lessons
7mThe first small-molecule oral GLP-1 option removes injection training and cold-chain handling, but daily dosing creates a different adherence job.
9mPeople do not stay on GLP-1 plans because they are disciplined forever. They stay on them when the plan feels manageable, repeatable, and clear enough to trust on a busy week.
9mMOTS-C keeps showing up in 2026 because it points at mitochondrial signaling. The trap is assuming that better signaling automatically means better recovery. It does not.
8mWeekly vs monthly is the real MariTide comparison. Here's how Amgen's conjugate stacks up conceptually against weekly dual/triple agonists — without fake head-to-heads.
9mThe real test for retatrutide is not whether it moves the scale. It is whether it makes the plan easier to follow without flattening training, energy, or lean mass.
8mRetatrutide's hype is not just about weight loss. The bigger story is the way a triple agonist can feel different, from warmth and energy expenditure to the GI side effects that shape adherence.
9mThe best metabolic tools do more than move the scale. They change how easy it is to follow the plan on day 3, day 30, and day 300.
8mThe scale is only part of the story. Retatrutide's biggest advantage may be how it quiets food noise and makes adherence easier to sustain.
Also available at /blog for legacy links.